ProCE Banner Activity

CME

Beyond the Face: Improving the Recognition and Treatment of Truncal Acne

BriefCase

Acne is one of the most common skin conditions seen in preadolescents and adolescents but truncal acne, while common, is typically overlooked and treated secondarily to facial acne. Truncal acne impairs quality of life, independently of facial acne severity. This CE/CME Briefcase emphasizes the importance of addressing the impact truncal acne can have on patients’ quality of life through appropriate diagnosis and treatment, including new treatments options that are specific for truncal acne. Patient cases illustrate key points in diagnosing and assessing the severity of acne, tools to determine the impact of truncal acne on quality of life, treatment regimens that are recommended to treat truncal acne, and strategies to individualize a treatment plan based on response and adverse events.

  AAPA
0.50 Credits
Release : August 16, 2022 | Expires : August 15, 2023
Begin Activity

Share

Faculty

Hilary Baldwin

Hilary Baldwin, MD

Clinical Associate Professor of Dermatology
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey
Medical Director
Acne Treatment and Research Center
Brooklyn, New York

Acknowledgement

This activity is supported by an educational grant from Galderma Laboratories, L.P.

Provided by

PACE

ProCE Banner

NAPNAP

ProCE Banner

Target Audience

NPs and PAs in dermatology, primary care, and pediatrics

Learning Objectives

After completing this activity, participants should be better able to:

Apply screening tools and strategies to assess the grade, severity, and impact of truncal acne in patients

Develop evidence-based approaches to individualize the treatment of patients with truncal acne

Disclosure

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Hilary Baldwin, MD: consultant/advisor/speaker: Almirall, Bausch, EPI, Galderma, Journey, Sun.

Kristine Kucera, PA-C: consultant/advisor/speaker: AbbVie, Amgen, Beiersdorf, Bristol-Myers Squibb, Dermavant, Leo, Novartis, Sun, UCB.

None of the members of the Planning Committee, PACE, NAPNAP, and PCE staff have any relevant financial relationships to disclose, except Kristine Kucera, PA-C as noted above.

CME Info

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 0.50 hours.

Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 67%.

Release date: August 16, 2022
Expiration date: August 15, 2023

Format

Case studies with interactive benchmarking

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of PACE or any educational supporter.

Accreditation

NAPNAP CE Contact Hours Designation

This program is accredited for 0.5 NAPNAP CE contact hours of which 0.5 contain pharmacology (Rx) content, per the National Association of Pediatric Nurse Practitioners Continuing Education Guidelines

NP course advisor: Faye Eifert, APRN, FNP-C, UT Southwestern and Children’s Medical Center, Dallas, Texas


PACE

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

AAPA Credit Designation

Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until August 15, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Kristine Kucera, PA-C, UT Southwestern Medical Center, Dallas, Texas

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credits for learning and change.